Table 6.
Association between anti-α-Gal antibody levels and risk of clinical malaria in multivariable logistic regression models.
| Antibody | All subjects together | Infants | Children | |||
|---|---|---|---|---|---|---|
| OR (CI) p-val | Covariates* | OR (CI) p-val | Covariates* | OR (CI) p-val | Covariates* | |
| IgG | 1.86 (1;3.5) 0.051 | Age, site, exposure | Site, exposure | 7.99 (1.54;58.03) 0.02 | Site, vaccine | |
| IgG1 | Age, site, exposure | Site, exposure | Site, vaccine | |||
| IgG2 | Age, site, exposure | Site, exposure | Site, vaccine | |||
| IgG3 | Age, site, exposure | Site, exposure | Site, vaccine | |||
| IgG4 | Age, site, exposure | Site, exposure | Site, vaccine | |||
| IgM | 0.38 (0.2;0.71) 0.003 | Site, exposure | 0.29 (0.1;0.77) 0.02 | Site, exposure | Site, vaccine | |
Data from phase 3 trial including all individuals together and stratified by age group, fitted including anti-α-Gal antibody data at M3 and adjusting by significant variables in univariate models to remove potential cofounding effects in the associations. P-values were adjusted for multiple comparisons. Data presented correspond to variables that were statistically significant.
*Covariates that in the multivariable analyses (backward and forward stepwise algorithms combined to obtain the model with the minimum akaike information criterion) were statistically significant. Age (Infants vs children); Site (Manhiça vs Kintampo); Exposure (malaria exposure antibody index); Vaccine (RTS,S vs comparator).